The company also announced a series of launches and updates, including a limited release of the Omnipod 5 App for iPhone. Insulet also made Omnipod 5 available in France and launched the system with expanded CGM integrations in the UK and the Netherlands.
Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM. It proactively corrects for highs and protects against lows with insulin dosing. The waterproof device features mobile app control for ease of use.
Acton, Massachusetts-based Insulet began a limited rollout of Omnipod 5 with G7 earlier this year. Omnipod 5 now works with the previous-generation G6 and the latest G7 sensor to offer more choices for people with type 1 diabetes.
The company plans to provide new customers with an updated starter kit that includes a new Omnipod 5, compatible with both sensors. This kit also includes a controller featuring user-selectable Dexcom CGM options. Insulet also plans to make a free, remote software update available to existing U.S. users the week of July 29.
Additionally, the company said it’s now the first and only one offering a tubeless automated insulin delivery system with full control from a compatible Android or iOS smartphone. Insulet plans to first launch its app with G6 integration, with G7 integration to follow. After this limited release, the company intends to communicate broadly when it makes the app available on the Apple App Store.
“Achieving these milestones demonstrates our company’s ongoing commitment to making our life-changing diabetes technology more accessible around the world,” said Jim Hollingshead, President and CEO. “With our recent expansion into France, Omnipod 5 is now accessible to the majority of our European customers. The integration of Dexcom G7 and the iPhone mobile app in the U.S. enables more options for those considering Omnipod 5 for their insulin delivery.”
Insulet has positive developments in Europe
Along with the U.S. developments, Insulet now offers Omnipod 5 in France to people with type 1 diabetes aged two years or older. It has compatibility with G6 in France and the company recently earned reimbursement in the country.
“Omnipod 5 has already had a huge impact on health outcomes for those with type 1 diabetes. Today, we celebrate the introduction of Omnipod 5 in France, which we know has been eagerly anticipated,” said Patrick Crannell, SVP and international GM. “The results of our studies demonstrate that Omnipod 5 improves quality of life and represents a significant advancement in diabetes management.”
Along with the France launch, Insulet made Omnipod 5 — with G6 and the Abbott FreeStyle Libre 2 Plus — fully available in the UK and the Netherlands. The company received CE mark for integration with Libre 2 Plus earlier this year.
Insulet said multiple sensor integrations give prescribers greater flexibility when recommending sensors for their patients. Customers can select their preferred sensor to connect to Omnipod 5 during the setup process.
“Expanding global access to Omnipod 5 is one of our top priorities,” Crannell said. “With the exciting, updated compatibility with both the Abbott FreeStyle Libre 2 Plus and the Dexcom G6 sensors, thousands more people with diabetes can enjoy the incredible freedom of tubeless, automated insulin delivery without having to change their CGM sensor brand. This is a game-changer for diabetes management.”